Olanzapine-induced pancreatitis: A case report

Journal of the Pancreas

Volumn 5, Issue 5, 2004, Pages 388-391

  Waage, Christian ^a   Carlsson, Hans ^a   Nielsen, Erik Waage ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antipsychotic agents adverse effects; Diabetes mellitus; Pancreatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; CHOLESTEROL; FLUCONAZOLE; GLUCOSE; HYPERTENSIVE FACTOR; INSULIN; LIPID; MEROPENEM; NEUROLEPTIC AGENT; OLANZAPINE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASCITES; CANDIDIASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EDEMA; HEART FAILURE; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTENSIVE CARE UNIT; KETOACIDOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; PANCREAS DISEASE; PANCREAS FUNCTION; PANCREAS FUNCTION TEST; PANCREAS PSEUDOCYST; PARANOID PSYCHOSIS; PATIENT MONITORING; POLYDIPSIA; POLYURIA; RESPIRATORY FAILURE; SURGICAL WARD; CHEMICALLY INDUCED DISORDER; PANCREATITIS;

ADULT; BENZODIAZEPINES; HUMANS; MALE; PANCREATITIS;

EID: 18044391558     PISSN: 15908577     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Medicines and Health Care. Oslo, Norway: Norwegian Association of Pharmaceutical Manufacturers, 2004. Page 86.
2. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20:844-7.
3. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23:1123-30.
4. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58:108-11
5. Cerulli TR. Clozapine-associated pancreatitis Harv Rev Psychiatry 1999; 7:61-3.
6. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40:438-43.
7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38.
8. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581-9.
9. Eli Lilly. Data Sheet. ZYPREYA™ & ZYPREXA ZYDIS™ Olanzapine tablets 2.5 mg, 5 mg, 10 mg. Olanzapine wafers 5 mg, 10 mg. Information for Health Proffesionals. Auckland, New Zealand: Eli Lilly and Company (NZ) Limited, 2004.
10. Wetterling T. Diabetes Mellitus Type II - Induced by 'Atypical' Neuroleptics? Fortschr Neurol Psychiatr 2003; 71:312-22.
11. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61:742-9.
12. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand 2002; 105:235-6.
13. Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. Ann Pharmacother 2000; 34:1128-31.
14. Hagger R, Brown C, Hurley P. Olanzapine and pancreatitis. Br J Psychiatry 2000; 177:567.
15. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35:1556-8.